Summary Box: Bristol-Myers liver cancer drug fails

AP News
|
Posted: Dec 22, 2011 6:07 PM
Summary Box: Bristol-Myers liver cancer drug fails

DRUG TEST: Bristol-Myers Squibb's experimental liver cancer drug brivanib didn't meet the main goal of a late-stage study. It was meant to show the pill could increase survival after patients worsened on another drug or couldn't tolerate it.

STILL ALIVE: The company is continuing three other late-stage studies of brivanib and will present detailed results from this one at a medical conference soon.

COMPANY FOCUS: Bristol-Myers is a major maker of cancer drugs, including Taxol for breast cancer, and also is developing drugs for liver diseases, both liver cancer and hepatitis B and C.